{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:22:11Z","timestamp":1792113731710,"version":"4.4.0"},"reference-count":38,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Italian Ministry of University Research","doi-asserted-by":"publisher","award":["20229ZA2YF"],"award-info":[{"award-number":["20229ZA2YF"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Semaglutide, a GLP-1R agonist (GLP-1RA), has demonstrated high efficacy in the management of type 2 diabetes. Few data in literature are available regarding the use of this agent in patients affected by latent autoimmune diabetes in adults (LADA). The purpose of this study is to analyze the efficacy of semaglutide use in patients affected by LADA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this retrospective study, we collected and analyzed data of 80 patients with LADA treated with semaglutide, either oral or subcutaneous, as an add-on therapy to insulin. Laboratory and clinical parameters and metrics from continuous glucose monitoring were collected where available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 80 patients, 68 continued semaglutide (57\/68 oral and 11\/68 subcutaneous) for at least 6 months, whereas 12\/80 patients discontinued treatment. After 6 months, semaglutide users showed statistically significant reduction in glycated hemoglobin, body mass index, and insulin total daily dose. Interestingly, serum C-peptide levels and the time-in-range values increased, without changes in the time below range. Subjects with residual \u03b2-cell function showed a higher body mass index and insulin total daily dose reduction. Moreover, the subgroup of subjects with preserved \u03b2-cell mass showed a greater improvement in time in range as compared to those with poor C-peptide production. Finally, 14\/68 subjects suspended insulin bolus administration after starting semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Semaglutide as an add-on treatment to insulin exerted relevant clinical beneficial effects on the glycometabolic control in patients with LADA. These effects are enhanced in those patients with preserved \u03b2-cell function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag072","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:33:49Z","timestamp":1771677229000},"page":"1842-1849","source":"Crossref","is-referenced-by-count":3,"title":["The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-3046","authenticated-orcid":false,"given":"Maria Elena","family":"Lunati","sequence":"first","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-0815","authenticated-orcid":false,"given":"Vincenzo","family":"Cimino","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, University of Milan , 20157 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Romano","sequence":"additional","affiliation":[{"name":"Diabetology, Azienda Ospedaliera ASST Sette Laghi - Osp. di Circolo , 21100 Varese ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Disoteo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Sant'Anna Hospital - ASST Lariana , 22100 Como ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, University of Milan , 20157 Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, University of Milano , 20157 Milan ,","place":["Italy"]},{"name":"IRCCS Ospedale Galeazzi-Sant'Ambrogio , 20157 Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Tinari","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Maria","family":"Fiorina","sequence":"additional","affiliation":[{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, University of Milan , 20157 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gandolfi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Silvia","family":"Morpurgo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"D\u2019Addio","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, University of Milan , 20157 Milan ,","place":["Italy"]},{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, University of Milan , 20157 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lazzaroni","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Losurdo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, University of Milan , 20157 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Pastore","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, University of Milan , 20157 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Molteni","sequence":"additional","affiliation":[{"name":"Centre for Diabetology, Endocrinology and Treatment of Metabolic Diseases, Sacra Famiglia Hospital , 22036 Erba ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Berra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, IRCCS Multimedica , 20099 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moufida","family":"Ben Nasr","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, University of Milan , 20157 Milan ,","place":["Italy"]},{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, University of Milan , 20157 Milan ,","place":["Italy"]},{"name":"Nephrology Division, Boston Children's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2096-8188","authenticated-orcid":false,"given":"Laura","family":"Montefusco","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Bucciarelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, University of Milan , 20157 Milan ,","place":["Italy"]},{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, University of Milan , 20157 Milan ,","place":["Italy"]},{"name":"Pio Albergo Trivulzio , 20146 Milan ,","place":["Italy"]},{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Universit\u00e0 di Milano , 20146 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1093-7724","authenticated-orcid":false,"given":"Paolo","family":"Fiorina","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, University of Milan , 20157 Milan ,","place":["Italy"]},{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, University of Milan , 20157 Milan ,","place":["Italy"]},{"name":"Nephrology Division, Boston Children's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"1 Suppl 1","key":"2026061619574461800_dgag072-B1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"10","key":"2026061619574461800_dgag072-B2","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1007\/s00125-020-05211-7","article-title":"The clinical consequences of heterogeneity within and between different diabetes types","volume":"63","author":"Redondo","year":"2020","journal-title":"Diabetologia"},{"key":"2026061619574461800_dgag072-B3","volume-title":"StatPearls","author":"Rajkumar","year":"2025"},{"issue":"3","key":"2026061619574461800_dgag072-B4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S2213-8587(20)30003-6","article-title":"Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)","volume":"8","author":"Maddaloni","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026061619574461800_dgag072-B5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1530\/EJE-14-0342","article-title":"High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7)","volume":"171","author":"Zampetti","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026061619574461800_dgag072-B6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41572-022-00390-6","article-title":"Adult-onset autoimmune diabetes","volume":"8","author":"Buzzetti","year":"2022","journal-title":"Nat Rev Dis Primer"},{"issue":"4","key":"2026061619574461800_dgag072-B7","doi-asserted-by":"crossref","first-page":"e3800","DOI":"10.1002\/dmrr.3800","article-title":"LADA 30th anniversary: a growing form of diabetes with persistent unresolved questions","volume":"40","author":"Lee Jia Jia","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"2026061619574461800_dgag072-B8","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00592-023-02115-x","article-title":"AWARE a novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus","volume":"60","author":"Berra","year":"2023","journal-title":"Acta Diabetol"},{"key":"2026061619574461800_dgag072-B9","doi-asserted-by":"crossref","first-page":"107517","DOI":"10.1016\/j.phrs.2024.107517","article-title":". Improved glycemic and weight control with dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study","volume":"210","author":"Berra","year":"2024","journal-title":"Pharmacol Res"},{"issue":"10","key":"2026061619574461800_dgag072-B10","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2337\/dbi20-0017","article-title":"Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel","volume":"69","author":"Buzzetti","year":"2020","journal-title":"Diabetes"},{"issue":"6","key":"2026061619574461800_dgag072-B11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/dom.13237","article-title":"Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials","volume":"20","author":"Pozzilli","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"2026061619574461800_dgag072-B12","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.3390\/jcm13216532","article-title":"Effectiveness and safety of GLP-1 receptor agonists in patients with type 1 diabetes","volume":"13","author":"Almohareb","year":"2024","journal-title":"J Clin Med"},{"issue":"4","key":"2026061619574461800_dgag072-B13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-024-03463-z","article-title":"Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial","volume":"31","author":"Pasqua","year":"2025","journal-title":"Nat Med"},{"key":"2026061619574461800_dgag072-B14","doi-asserted-by":"crossref","first-page":"111593","DOI":"10.1016\/j.diabres.2024.111593","article-title":"Effect of low dose semaglutide in people with type 1 diabetes and excess weight","volume":"209","author":"Grassi","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2026061619574461800_dgag072-B15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/dc15-0258","article-title":"Markers of \u03b2-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes","volume":"39","author":"Jones","year":"2016","journal-title":"Diabetes Care"},{"key":"2026061619574461800_dgag072-B16","doi-asserted-by":"crossref","first-page":"105782","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-diabetic drugs and weight loss in patients with type 2 diabetes","volume":"171","author":"Lazzaroni","year":"2021","journal-title":"Pharmacol Res"},{"issue":"4","key":"2026061619574461800_dgag072-B17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/clinem\/dgac618","article-title":"Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study","volume":"108","author":"Edwards","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026061619574461800_dgag072-B18","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"2026061619574461800_dgag072-B19","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"2026061619574461800_dgag072-B20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"10","key":"2026061619574461800_dgag072-B21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMc2302677","article-title":"Semaglutide in early type 1 diabetes","volume":"389","author":"Dandona","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2026061619574461800_dgag072-B22","doi-asserted-by":"crossref","first-page":"EVIDoa2500173","DOI":"10.1056\/EVIDoa2500173","article-title":"Semaglutide in adults with type 1 diabetes and obesity","volume":"4","author":"Shah","year":"2025","journal-title":"NEJM Evid"},{"issue":"2","key":"2026061619574461800_dgag072-B23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2337\/ds20-0093","article-title":"Clinical application of time in range and other metrics","volume":"34","author":"Aleppo","year":"2021","journal-title":"Diabetes Spectr Publ Am Diabetes Assoc"},{"issue":"8","key":"2026061619574461800_dgag072-B24","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"11","key":"2026061619574461800_dgag072-B25","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"issue":"39","key":"2026061619574461800_dgag072-B26","doi-asserted-by":"crossref","first-page":"e39799","DOI":"10.1097\/MD.0000000000039799","article-title":"GLP-1 receptor agonist\u2013induced diabetic ketoacidosis: a case report","volume":"103","author":"Zhang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"2026061619574461800_dgag072-B27","doi-asserted-by":"crossref","first-page":"23247096231206333","DOI":"10.1177\/23247096231206333","article-title":"Euglycemic diabetic keto acidosis in a type 1 diabetic patient after glucose like peptide-1 administration: a case presentation","volume":"11","author":"Widhalm","year":"2023","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"2","key":"2026061619574461800_dgag072-B28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.numecd.2021.10.003","article-title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system","volume":"32","author":"Yang","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"2026061619574461800_dgag072-B29","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","article-title":"Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets","volume":"144","author":"Farilla","year":"2003","journal-title":"Endocrinology"},{"issue":"4","key":"2026061619574461800_dgag072-B30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/jcm14041303","article-title":"Unveiling the therapeutic potential of the second-generation incretin analogs semaglutide and tirzepatide in type 1 diabetes and latent autoimmune diabetes in adults","volume":"14","author":"Infante","year":"2025","journal-title":"J Clin Med"},{"key":"2026061619574461800_dgag072-B31","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"issue":"6","key":"2026061619574461800_dgag072-B32","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","article-title":"Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule","volume":"36","author":"Nasr M","year":"2024","journal-title":"Cell Metab"},{"issue":"2","key":"2026061619574461800_dgag072-B33","doi-asserted-by":"crossref","first-page":"e55-e58","DOI":"10.1016\/j.diabres.2013.01.020","article-title":"Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study","volume":"100","author":"Hari Kumar","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2026061619574461800_dgag072-B34","doi-asserted-by":"crossref","first-page":"101433","DOI":"10.1016\/j.diabet.2023.101433","article-title":"Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): a randomized double-blind placebo-controlled trial","volume":"49","author":"Thivolet","year":"2023","journal-title":"Diabetes Metab"},{"issue":"11","key":"2026061619574461800_dgag072-B35","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/dom.14121","article-title":"Exenatide extended release in patients with type 1 diabetes with and without residual insulin production","volume":"22","author":"Herold","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2026061619574461800_dgag072-B36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of \u03b2-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2026061619574461800_dgag072-B37","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/dom.13613","article-title":"The effects of incretin-based therapies on \u03b2-cell function and insulin resistance in type 2 diabetes: a systematic review and network meta-analysis combining 360 trials","volume":"21","author":"Wu","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2026061619574461800_dgag072-B38","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/dom.15554","article-title":"Oral or injectable semaglutide for the management of type 2 diabetes in routine care: a multicentre observational study comparing matched cohorts","volume":"26","author":"Fadini","year":"2024","journal-title":"Diabetes Obes Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag072\/67075775\/dgag072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/1842\/67075775\/dgag072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/1842\/67075775\/dgag072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:57:52Z","timestamp":1781654272000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/1842\/8495028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag072","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,23]]}}}